Unveiling therapeutic avenues targeting xCT in head and neck cancer

Area of Science:

• Oncology
• Cancer Biology
• Molecular Medicine

Background:

• Head and neck cancer (HNC) presents a significant global health challenge.
• Current therapeutic strategies for HNC require innovation to improve patient outcomes.
• The cystine/glutamate antiporter (xCT) is increasingly recognized for its role in cancer progression.

Purpose of the Study:

• To review the multifaceted role of xCT in head and neck cancer (HNC) progression.
• To elucidate the mechanisms by which xCT contributes to HNC, including redox imbalance, ferroptosis, and treatment resistance.
• To evaluate the therapeutic potential of targeting xCT in HNC.

Main Methods:

• Comprehensive literature review of studies investigating xCT in HNC.
• Analysis of xCT's contribution to tumor biology and its impact on therapeutic resistance.
• Examination of current and emerging xCT-targeted therapies and treatment modalities.

Main Results:

• xCT dysregulation significantly influences HNC tumor biology.
• xCT promotes cancer progression via mechanisms including redox imbalance and ferroptosis induction.
• xCT activity is linked to resistance against conventional HNC treatments.
• Emerging xCT inhibitors show potential for enhancing HNC therapy.

Conclusions:

• xCT is a critical mediator of HNC progression and therapeutic resistance.
• Targeting xCT represents a promising therapeutic strategy for improving HNC treatment outcomes.
• Further research and clinical application of xCT-targeted therapies are warranted for HNC management.